Active ingredientBelzutifanCat. No. P-B021-001CAS 1672668-24-4Family · Pharmaceutical analytical standards
Belzutifan
An oral inhibitor of HIF-2 alpha, a protein that drives the growth of some tumours when oxygen is lacking or when the VHL gene does not work. Approved in the United States in 2021, it was the first medicine for tumours associated with von Hippel-Lindau disease. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?It grew out of Nobel-winning science: William Kaelin and Peter Ratcliffe showed that the VHL protein controls HIF levels, work on how cells sense oxygen that earned the 2019 Nobel Prize in Medicine, shared with Gregg Semenza.
Go to the active ingredient →Active ingredientBelzutifanCat. No. P-B021-001CAS 1672668-24-4
MetaboliteBelzutifan O-GlucuronideCat. No. P-B021-002CAS 2370102-07-9
Isotopically labelledBelzutifan-13C-d3Cat. No. P-B021-003
ImpurityBelzutifan Impurity 1Cat. No. P-B021-004CAS 1672668-51-7
ImpurityBelzutifan Impurity 2Cat. No. P-B021-005
ImpurityBelzutifan Impurity 3Cat. No. P-B021-006CAS 3004833-91-1
ImpurityBelzutifan Impurity 4Cat. No. P-B021-007CAS 1672668-57-3
ImpurityBelzutifan Impurity 5Cat. No. P-B021-010CAS 2738682-45-4
ImpurityBelzutifan Impurity 6Cat. No. P-B021-011CAS 2738682-44-3
ImpurityBelzutifan Impurity 7Cat. No. P-B021-012CAS 2738682-43-2No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.